Crucell gets NIAID influenza contract

Crucell N.V. (Euronext:CRXL; NASDAQ:CRXL) received a five-year contract for up to $40.7 million from NIH's National Institute of Allergy and Infectious Diseases (NIAID) to use the company's MAbstract ...